American Family Children's Hospital
SHARE TEXT
Mark A. Ritter, MD, PhD close
4P7Dt9O906U
Mark A. Ritter, MD, PhD
 


For Patients

Need help selecting a doctor?
Call the Welcome Center at
(608) 821-4819 for personal assistance.

For Referring Physicians

How to refer a patient

Mark A. Ritter, MD, PhD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Ritter specializes in treating patients with gastrointestinal and genitourinary cancers, including liver and pancreas, colon, stomach, bladder, prostate, testicular and kidney.

Specialties

Oncology (Radiation)

UW Health Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
University Hospital
(608) 263-7502 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 263-8500 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 263-4757 | (800) 323-8942 | Map

Hospital Affiliation(s)

University Hospital (primary)
UnityPoint Health - Meriter (secondary)

UW School of Medicine and Public Health

Department of Human Oncology

Professional Certifications and Education

Board Certification Radiation Oncology
Residency Hospital of the University of Pennsylvania
Internship Hospital of the University of Pennsylvania
Medical School University of Miami Miller School of Medicine, Miami, FL, 1984

Awards/Honors

Madison Magazine Top Docs 2016

Best Doctors® in America 2015

Best Doctors® in America 2014

Best Doctors® in America 2013

Madison Magazine Top Docs 2012

Best Doctors® in America 2011


Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
Research

Dr. Ritter’s research involves the investigation of biology and technology-driven optimization of treatment for prostate cancer.


PubMed Articles
Brower JV Chen S Bassetti MF Yu M Harari PM Ritter MA Baschnagel AM . Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012. Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):985-993
[PubMed ID: 27869098]
Johnson SB Soulos PR Shafman TD Mantz CA Dosoretz AP Ross R Finkelstein SE Collins SP Suy S Brower JV Ritter MA King CR Kupelian PA Horwitz EM Pollack A Abramowitz MC Hallman MA Faria S Gross CP Yu JB . Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol. 2016 Nov 24;
[PubMed ID: 27890426]
Morris ZS Saha S Magnuson WJ Morris BA Borkenhagen JF Ching A Hirose G McMurry V Francis DM Harari PM Chappell R Tsuji S Ritter MA . Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Cancer. 2016 Aug 15;122(16):2487-95
[PubMed ID: 27203227]
Brower JV Forman JD Kupelian PA Petereit DG Gondi V Lawton CA Anger N Saha S Chappell R Ritter MA . Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer. Radiother Oncol. 2016 Jan;118(1):99-104
[PubMed ID: 26755165]
Yu J Hardcastle N Jeong K Bender ET Ritter MA Tomé WA . On voxel-by-voxel accumulated dose for prostate radiation therapy using deformable image registration. Technol Cancer Res Treat. 2015 Feb;14(1):37-47
[PubMed ID: 24354754]
Jarrard DF Blute ML Jr Ritter MA . Potential role for androgen-deprivation therapy and pelvic radiation therapy in node-positive postprostatectomy prostate cancer. J Clin Oncol. 2014 Dec 10;32(35):3926-9
[PubMed ID: 25332250]
Petereit DG Hahn LJ Kanekar S Boylan A Bentzen SM Ritter M Moser AR . Prevalence of ATM Sequence Variants in Northern Plains American Indian Cancer Patients. Front Oncol. 2013 Dec 30;3:318
[PubMed ID: 24416720]
Verhoven B Yan Y Ritter M Khor LY Hammond E Jones C Amin M Bahary JP Zeitzer K Pollack A . Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08. Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):317-23
[PubMed ID: 23474109]
Babaian K Truong M Cetnar J Cross DS Shi F Ritter MA Jarrard DF . Analysis of urological procedures in men who died from prostate cancer using a population-based approach. BJU Int. 2013 Mar;111(3 Pt B):E65-70
[PubMed ID: 23130676]
Fashoyin A Hartig G Schelman WR Ritter M Agni R Gopal DV Pfau PR Weiss JM . Aggressive adenocarcinoma of the cervical esophagus: importance of a multidisciplinary approach. Case Rep Gastrointest Med. 2012;2012:826246
[PubMed ID: 23304576]
Adkison JB McHaffie DR Bentzen SM Patel RR Khuntia D Petereit DG Hong TS Tomé W Ritter MA . Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):184-90
[PubMed ID: 21163590]
Kruser TJ Jarrard DF Graf AK Hedican SP Paolone DR Wegenke JD Liu G Geye HM Ritter MA . Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer. 2011 Jun 15;117(12):2629-36
[PubMed ID: 21656740]
Schubert LK Westerly DC Tomé WA Mehta MP Soisson ET Mackie TR Ritter MA Khuntia D Harari PM Paliwal BR . A comprehensive assessment by tumor site of patient setup using daily MVCT imaging from more than 3,800 helical tomotherapy treatments. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1260-9
[PubMed ID: 19251098]
Ritter M Forman J Kupelian P Lawton C Petereit D . Hypofractionation for prostate cancer. Cancer J. 2009 Jan-Feb;15(1):1-6
[PubMed ID: 19197165]
Ritter M . Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin Radiat Oncol. 2008 Oct;18(4):249-56
[PubMed ID: 18725112]
Hutson PR Oettel K Douglas J Ritter M Messing E Staab MJ Alberti D Horvath D Wilding G . Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test. Cancer Chemother Pharmacol. 2008 Aug;62(3):373-7
[PubMed ID: 17922273]
Wong GW Palazzi-Churas KL Jarrard DF Paolone DR Graf AK Hedican SP Wegenke JD Ritter MA . Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):449-55
[PubMed ID: 17869014]
Ritter MA . Prognostic and predictive markers in radiation therapy: focus on prostate cancer. Cancer Treat Res. 2008;139:97-114
[PubMed ID: 18236713]
Hong TS Welsh JS Ritter MA Harari PM Jaradat H Mackie TR Mehta MP . Megavoltage computed tomography: an emerging tool for image-guided radiotherapy. Am J Clin Oncol. 2007 Dec;30(6):617-23
[PubMed ID: 18091057]
Allen GW Howard AR Jarrard DF Ritter MA . Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer. 2007 Oct 1;110(7):1405-16
[PubMed ID: 17685384]